Abstract
Abstract
Background
A simultaneous integrated boost (SIB) may result in increased out-of-field (DOOF) and photoneutron (HPN) doses in volumetric modulated arc therapy (VMAT) for prostate cancer (PCA). This work therefore aimed to compare DOOF and HPN in flattened (FLAT) and flattening filter-free (FFF) 6‑MV and 10-MV VMAT treatment plans with and without SIB.
Methods
Eight groups of 30 VMAT plans for PCA with 6 MV or 10 MV, with or without FF and with uniform (2 Gy) or SIB target dose (2.5/3.0 Gy) prescriptions (CONV, SIB), were generated. All 240 plans were delivered on a slab-phantom and compared with respect to measured DOOF and HPN in 61.8 cm distance from the isocenter. The 6‑ and 10-MV flattened VMAT plans with conventional fractionation (6- and 10-MV FLAT CONV) served as standard reference groups. Doses were analyzed as a function of delivered monitor units (MU) and weighted equivalent square field size Aeq. Pearson’s correlation coefficients between the presented quantities were determined.
Results
The SIB plans resulted in decreased HPN over an entire prostate RT treatment course (10-MV SIB vs. CONV −38.2%). Omission of the flattening filter yielded less HPN (10-MV CONV −17.2%; 10-MV SIB −22.5%). The SIB decreased DOOF likewise by 39% for all given scenarios, while the FFF mode reduced DOOF on average by 60%. A strong Pearson correlation was found between MU and HPN (r > 0.9) as well as DOOF (0.7 < r < 0.9).
Conclusion
For a complete treatment, SIB reduces both photoneutron and OOF doses to almost the same extent as FFF deliveries. It is recommended to apply moderately hypofractionated 6‑MV SIB FFF-VMAT when considering photoneutron or OOF doses.
Funder
Ruprecht-Karls-Universität Heidelberg
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Radiology, Nuclear Medicine and imaging
Reference35 articles.
1. Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R et al (2022) NCCN Guidelines(R) Insights: Prostate Cancer, Version 1.2023. J Natl Compr Canc Netw 20:1288–1298
2. German S3 Evidence-Based Guideline For the therapy of Prostate Cancer Leitlinienprogramm onkologie (Deutsche Krebsgesellschaft DK, AWMF): S3-leitlinie prostatakarzinom, leitlinienreport, version 6.0, Mai 2021, AWMF registernummer: 043/022OL. German S3 Evidence-Based Guideline For the therapy of Prostate Cancer 2021.
3. Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5‑year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17:1047–1060
4. Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W et al (2019) Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 20:1531–1543
5. Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM et al (2017) Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 35:1884–1890